Synthroid (Levothyroxine) and Rosuvastatin Interaction: Safety, Timing, and Monitoring
Levothyroxine (brand name Synthroid, a T4 thyroid hormone replacement) and rosuvastatin (brand name Crestor, an HMG-CoA reductase inhibitor/statin) are commonly prescribed together because hypothyroidism and elevated LDL cholesterol frequently coexist. There is no documented pharmacokinetic interaction between the two drugs. The interaction that matters clinically is pharmacodynamic: uncontrolled hypothyroidism raises LDL cholesterol on its own and is listed on statin labeling as a condition that increases the risk of statin-associated myopathy. Correcting thyroid status changes both the lipid picture and the muscle-safety picture, which is why timing and monitoring matter more than dose spacing alone.
Levothyroxine and rosuvastatin do not share a metabolic pathway that would cause a direct drug-drug interaction: rosuvastatin undergoes minimal CYP2C9 metabolism and is largely excreted unchanged, while levothyroxine is deiodinated and conjugated in peripheral tissue and liver with no meaningful CYP involvement. The FDA-approved rosuvastatin label lists hypothyroidism among conditions that predispose to myopathy and rhabdomyolysis, independent of any interaction with levothyroxine itself (FDA, rosuvastatin label, accessed 2023). No dedicated interaction trial between these two drugs has been identified in the sources reviewed for this page; the guidance below reflects labeling and general endocrine and lipid pharmacology rather than a rosuvastatin-levothyroxine-specific study, and that gap should be verified against current product labeling before treating any numeric claim as settled.
Why this pairing is common, and why timing matters more than most people expect
Thyroid hormone helps regulate hepatic LDL-receptor expression. When thyroid hormone levels fall, LDL clearance slows and LDL-C rises. It is plausible, and consistent with general endocrinology, that a patient started on a statin while still significantly hypothyroid is being treated for a lipid abnormality that thyroid replacement alone could partly or fully correct. The magnitude of that effect varies by how hypothyroid the patient is and how long it has gone untreated; exact percentage reductions reported in older literature should be confirmed against current studies rather than quoted as fixed numbers for an individual patient.
Levothyroxine has a narrow therapeutic index and needs a consistent, low-interference environment to absorb reliably. The FDA levothyroxine label instructs patients to take it on an empty stomach, generally 30 to 60 minutes before food, and to separate it from calcium, iron, and other mineral-containing products that can reduce its absorption (FDA, levothyroxine/Synthroid label, accessed 2017 label version). Rosuvastatin does not contain minerals known to bind levothyroxine, and no published absorption interaction between the two drugs has been established. Even so, spacing the two medications by at least a few hours is standard, low-cost practice that avoids any theoretical competition for absorption and simplifies adherence.
The pharmacodynamic overlap: lipids and muscle risk
This is the part of the interaction with an actual evidence anchor in labeling and guideline-level knowledge, as opposed to a mechanistic interaction between the molecules themselves.
Lipids. Overt hypothyroidism is an established cause of elevated total cholesterol and LDL-C, and treating it with levothyroxine is expected to lower LDL-C to some degree, though the exact amount depends on baseline severity and individual response. A patient whose LDL-C is elevated while TSH is also abnormal has an ambiguous lipid picture until thyroid status is corrected. Starting a statin at the same visit makes it impossible to tell how much of any subsequent LDL-C improvement came from the statin versus from thyroid correction.
Muscle risk. Statin labeling identifies hypothyroidism as a condition that increases susceptibility to myopathy and rhabdomyolysis. The mechanistic explanation commonly cited is that hypothyroid skeletal muscle has reduced oxidative capacity, which compounds the muscle stress statins can cause. This is a recognized labeling caution, not a quantified fold-increase specific to rosuvastatin; any precise relative-risk number attached to this combination should be checked against a primary source before being repeated to a patient.
Practical timing
- Take levothyroxine on an empty stomach, ideally 30 to 60 minutes before food, consistently at the same time each day.
- Rosuvastatin has a long half-life (labeled around 19 hours) and can generally be taken at any time of day, unlike short-acting statins that are often dosed in the evening.
- A separation of at least several hours between the two drugs is a reasonable, low-burden default. If a patient prefers bedtime levothyroxine dosing taken well after the last meal, that is an accepted alternative to morning dosing as long as it stays separated from food, calcium, iron, and other interacting substances.
Should you recheck lipids right after starting levothyroxine?
Repeating a lipid panel too soon after starting or adjusting levothyroxine risks attributing a change to the wrong drug, or missing that thyroid correction alone resolved the lipid abnormality. A reasonable sequence, consistent with the general principle in thyroid and lipid management guidance, is:
- Start or adjust levothyroxine; recheck TSH roughly 6 to 8 weeks later, since levothyroxine dose changes take that long to reach steady state.
- Once TSH is within target range, allow additional time for lipids to re-equilibrate before drawing conclusions.
- Repeat a fasting lipid panel once TSH has been stable, then decide whether statin therapy is still indicated at the new LDL-C level.
- If a patient is already established on rosuvastatin when hypothyroidism is newly diagnosed, the reasonable approach is to continue the statin, correct the thyroid disorder, and reassess statin dose or need afterward rather than stopping the statin abruptly.
This sequencing reflects a widely cited principle in thyroid management, that thyroid-driven dyslipidemia should be reassessed after euthyroidism is achieved, but the specific numeric intervals above should be confirmed against current ATA and ACC/AHA guideline text rather than treated as fixed.
Monitoring while on both medications
- Thyroid function: recheck TSH after any levothyroxine dose change, generally around 6 to 8 weeks later, then at a stable interval once TSH is in range. Biotin supplements are known to interfere with some thyroid immunoassays and can produce falsely abnormal TSH results; stopping biotin for a couple of days before labs is a common precaution, though the exact recommended interval should be confirmed with the lab performing the assay.
- Lipids: recheck after thyroid status has stabilized, then at whatever interval fits the patient's cardiovascular risk category.
- Muscle symptoms: routine CK testing in asymptomatic patients is not generally recommended. New muscle pain, weakness, or dark urine warrants checking both CK and TSH together, because hypothyroid myopathy and statin myopathy can look similar and the thyroid result changes the interpretation. A markedly elevated CK is a reason to stop the statin and seek prompt medical evaluation rather than wait it out.
Special populations
Older adults. People over 65 are more likely to have both hypothyroidism and dyslipidemia, and are generally more susceptible to statin-related muscle effects. Many clinicians start statin doses lower in this group and titrate slowly; individual dosing decisions should be made with a prescriber, not from this page.
Pregnancy. Levothyroxine dose requirements typically increase during pregnancy due to rising thyroxine-binding globulin, and dosing should be managed by the treating clinician with trimester-specific targets. Rosuvastatin is contraindicated in pregnancy per its FDA label. A patient on both drugs who becomes pregnant or is planning pregnancy should discuss stopping rosuvastatin with her prescriber promptly.
Kidney disease. The rosuvastatin label caps the dose at 10 mg daily in patients with significantly reduced kidney function (eGFR under 30). Levothyroxine dosing is not meaningfully altered by kidney impairment, but reduced kidney function and untreated hypothyroidism can both independently raise myopathy risk, which argues for closer muscle-symptom monitoring in this group.
Is rosuvastatin the right statin choice for a hypothyroid patient?
Rosuvastatin's minimal reliance on CYP enzymes is generally considered an advantage in patients on multiple medications, since it reduces the chance of drug-drug metabolic conflicts compared with statins that are CYP3A4 substrates (atorvastatin, simvastatin, lovastatin). This is a general pharmacologic property, not evidence that rosuvastatin is safer specifically in hypothyroid patients; head-to-head data comparing statin choice by thyroid status were not available in the sources used for this page and should be checked directly with a clinician or pharmacist before treating one statin as preferable for this specific population.
Evidence-status interaction assessment
| Question | Established | Plausible, not proven | Not established / needs verification |
|---|---|---|---|
| Do levothyroxine and rosuvastatin share a metabolic pathway that causes a PK interaction? | No shared CYP/transporter conflict is described in current rosuvastatin metabolism labeling | , | A dedicated head-to-head PK interaction study between these two specific drugs was not identified |
| Does timing separation matter? | Levothyroxine absorption is reduced by concurrent minerals (calcium, iron); general spacing from other oral drugs is standard label guidance | A specific 4-hour rule for rosuvastatin in particular prevents any measurable absorption change | Rosuvastatin itself binding or reducing levothyroxine absorption has not been documented |
| Does correcting hypothyroidism lower LDL-C? | Yes, as a general endocrine and lipid principle; overt hypothyroidism is an established cause of elevated LDL-C | The exact magnitude of LDL-C change for a given patient | A universal numeric LDL-C reduction that applies across all patients |
| Does hypothyroidism raise statin myopathy risk? | Yes, hypothyroidism is listed on statin labeling as a condition predisposing to myopathy | The degree to which this risk compounds specifically with rosuvastatin versus other statins | A precise quantified relative risk for this exact combination |
| What should a clinician or pharmacist verify before relying on this page? | , | , | Current FDA label language (labels are periodically updated), current ATA and ACC/AHA guideline text on sequencing thyroid and lipid treatment, and any patient-specific dosing decision |
What to tell your prescriber or pharmacist
Mention all medications, including levothyroxine, before starting or continuing rosuvastatin. Report new or unexplained muscle pain, tenderness, weakness, or dark urine promptly rather than waiting for a routine visit. Do not stop either medication on your own; if muscle symptoms appear, the first step is usually confirming current TSH and CK levels, not automatically discontinuing the statin.
Evidence boundary
Established: no known pharmacokinetic interaction between levothyroxine and rosuvastatin; hypothyroidism is a labeled risk factor for statin-associated myopathy; hypothyroidism raises LDL-C and correcting it can lower LDL-C; levothyroxine absorption is reduced by concurrent minerals and is best taken on an empty stomach separate from other oral medications.
Plausible but not proven from the sources reviewed here: a specific 4-hour separation window as the precise threshold that prevents any interaction; a fixed timeline (in weeks) that applies uniformly to every patient for rechecking lipids after thyroid correction; any claim that rosuvastatin or pitavastatin is meaningfully safer than other statins specifically in hypothyroid patients.
Not established, or requiring direct verification against primary literature and current labeling before being repeated as fact: exact percentage or fold-increase figures for myopathy risk in this specific drug combination, and any quantified LDL-C change (in mg/dL) attributable to thyroid correction alone in a mixed patient population.
References
No dedicated primary-literature search for a levothyroxine-rosuvastatin interaction study returned a verifiable result at the time this page was drafted. Claims above that rely on general endocrine, lipid, or statin-safety knowledge rather than a specific trial are labeled as such, and any numeric detail a reader intends to act on should be confirmed with a pharmacist or the treating clinician against current guideline text and product labeling.